

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 August 2005 (18.08.2005)

PCT

(10) International Publication Number
WO 2005/075416 A1

(51) International Patent Classification⁷: **C07C 311/37**,
A61K 31/18, A61P 35/00

(21) International Application Number:
PCT/EP2005/000875

(22) International Filing Date: 28 January 2005 (28.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P-200400032 29 January 2004 (29.01.2004) SI

(71) Applicant (*for all designated States except US*): **LEK
PHARMACEUTICALS D.D.** [SI/SI]; Verovskova 57,
1526 Ljubljana (SI).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **HAM, Zoran** [SI/SI];
Trg Franca Fakina 7, 1420 Trbovlje (SI).

(74) Agent: **DIETZ, Joerg**; Novartis AG, Corporate Intellec-
tual Property, CH-4002 Basel (CH).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: AMORPHOUS TAMSULOSIN HYDROCHLORIDE

(57) Abstract: In the present invention, amorphous tamsulosin hydrochloride, the process for preparation thereof by lyophilisation or spray-drying and the properties thereof are disclosed. Amorphous tamsulosin hydrochloride is useful in the preparation of pharmaceutical formulations for use particularly in the treatment of benign prostatic hyperplasia.

